GB 106
Alternative Names: GB-106Latest Information Update: 15 Jan 2024
At a glance
- Originator G & P Bioscience
- Class Antihaemorrhagics; Gene therapies
- Mechanism of Action Factor VIII replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Haemophilia A
Most Recent Events
- 13 Oct 2023 G & P Bioscience has patent protection for GB 106 in South Korea, Japan and Australia (G & P Bioscience pipeline, October 2023)
- 13 Oct 2023 G & P Bioscience files for patent protection for GB 106 in multiple countries (G & P Bioscience pipeline, October 2023)
- 13 Oct 2023 Early research in Haemophilia A in South Korea (Parenteral) (G & P Bioscience pipeline, October 2023)